



UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)	Group Art Unit: 1648
)	
Fang Fang et al.)	Examiner: Winkler, Ulrike
)	
Serial No.: 09/555,446)	Confirmation No.: 9403
)	
Filed: August 16, 2000)	Customer No.: 53897
)	
For: Multivalent Recombinant Antibodies)	
For Treating HRV Infections)	
)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
 Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed with an RCE in the above-captioned application, thus, it is believed that no fee is due in connection with this submission. However, if it is determined that a fee is due, the Commissioner is hereby authorized to charge the requisite fee, or any fees that may be due in connection with this and the attached papers, or with this application during its entire pendency, or to credit any overpayment, to Deposit Account No. 04-1679.


In accordance with 37 C.F.R. §1.56 and 37 C.F.R. §§1.97-1.98, this Information Disclosure Statement, including Form PTO/SB/08 (3 pages), and cited documents, are provided herewith.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

May 11, 2006
 Date of Deposit

Roxanne Ippolito
 Name of Person Mailing Paper


 Signature of Person Mailing Paper

In addition, Applicant would like to cross-reference the following U.S. applications:

U.S. App. Serial. No. **Filing Date**

09/674,014	02/08/2001
09/910,483	07/19/2001
10/199,957	07/19/2002

PCT App. Serial No. **Filing Date**

PCT/US02/23303	07/19/2002
PCT/US02/23002	07/19/2002
PCT/US98/25422	11/30/1998
PCT/UIS99/06537	04/19/1999

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 C.F.R. §1.56. The filing of this Information Disclosure Statement is not an admission by Applicants or Applicants' representatives that any of the documents, singly or in any combination, is effective as prior art against the subject application. Additionally, in accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists in addition to those submitted herewith.

Applicants respectfully request that the Examiner review the foregoing documents and information and that they be made of record in the file history of the subject application.

Respectfully submitted,

By:


James W. Collett, Ph.D.
Reg. No. 46,636

DUANE MORRIS LLP
101 West Broadway, Suite 900
San Diego, CA 92101-8285
(O) (619) 744-2200
(F) (619) 744-2201

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. E3799-00018	Application No. 09/555,446
Information Disclosure Statement by Applicant (Use several sheets if necessary) <small>(37 CFR § 1.13(b))</small>				Applicant Fang Fang	
		Filing Date 08/16/2000	Group Art Unit 1648		

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5077195	12/1991	Blalock			
	AB	5081584	01/14/1992	Omichinski			
	AC	5223409	06/29/1993	Ladner			
	AD	5530101	06/1996	Queen			
	AE	5639641	06/1997	Pedersen			
	AF	5723286	03/1998	Dower			
	AG	5821123	10/1998	Studnicka			
	AH	5821337	10/1998	Carter			
	AI	6129914	10/2000	Weiner			
	AJ	6329511	12/2001	Vasquez			
	AK	6800735	10/05/2004	Whitty et al.			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	AL	90/07861	07/1990	WIPO			
	AM	91/07418	05/1991	WIPO			
	AN	91/07493	05/1991	WIPO			
	AO	91/07494	05/1991	WIPO			
	AP	92/11018	07/1992	WIPO			
	AQ	92/22653	12/1992	WIPO			
	AR	93/06213	04/1993	WIPO			
	AS	93/11794	06/1993	WIPO			
	AT	94/04679	03/1994	WIPO			
	AU	0239400 A2	09/1987	Europe			
	AV	0239400 B1	09/1987	Europe			
	AW	0387701 B1	09/1990	Europe			
	AX	0404003 A2	12/1990	Europe			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3799-00018	Application No. 09/555,446
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Fang Fang		
		Filing Date 08/16/2000	Group Art Unit 1648	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AY	0459577	04/1991	Europe				
	AZ	0451216 B1	10/1991	Europe				
	AAA	0605522 B1	07/1994	Europe				
	ABB	365837 B1	08/1995	Europe				
	ACC	0682040 A1	11/1995	Europe				
	ADD	0682040 B1	11/1995	Europe				
	AEE	0939127 A2	09/1999	Europe				
	AFF	0967277 A2	12/1999	Europe				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AGG	Ohtomo, et al., "Humanization of Mouse ONS-M21 Antibody With The Aid of Hybrid Variable Regions", (1995) Molecular Immunology, Vol. 1, No. 6, pp. 407-416
	AHH	Mateo, et al., "Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity," (1997), Immunotechnology, Vol. 3, pp. 71-81
	AII	Nagahria, et al., "Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor- α (TNF- α)," (1999), Journal of Immunological Methods, Vol. 222, pp. 83-92
	AJJ	Saldanha, et al., "A single blackmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," (1999). Molecular Immunology, Vol. 36, pp. 709-719
	AKK	Tempest, et al., "Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus," (1995), Int. J. Biol. Macromol., Vol. 17, No. 1, pp. 37-42
	ALL	Carter, et al., "Humanization of an anti-p185(HER2) antibody for human cancer therapy", (1992), Proc. Natl. Acad. Sci., Vol. 89, pp. 4285-4289
	AMM	Presta, et al., "Humanization of an Antibody Directed Against IgE", (1993), Journal of Immunology, Vol. 151, No. 5, pp. 2623-2632
	ANN	Padlan (1994) molecular immunol, 31: 169-217
	AOO	Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," Proc Natl Acad Sci USA, 1982, Vol. 79, pp. 1979-1893
	APP	Fox, J., "No winner against AIDS", Bio/Technology, Vol. 12 (Feb 1994), pp 128
	AQQ	Ockenhouse et al., "Plasmodium falciparum-infected erythrocytes bind ICAM-1 at a site distinct from LFA-1, MAC-1, and Human Rhinovirus", Cell 68 (1), 1992, pp. 63-69
	ARR	Cruse et al., Illustrated dictionary of immunology, 2 nd edition, CRC Press, 2003, pp. 341
	ASS	Bastiani et al., "Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions", Journal of Virology, May 1997, pp. 3444-3450
Examiner Signature		Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No: E3799-00018	Application No. 09/555,446
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Fang Fang		
		Filing Date 08/16/2000	Group Art Unit 1648	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ATT	Fahey et al., "A Status of immune-based therapies in HIV infection and AIDS", Clinical and Experimental Immunology, Vol. 88 (1992), pp 1-5
	AUU	Crowe et al. Vaccine. 2002; 20: S32-S37
	AVV	Padlan (1991) molecular immunol, 28: 489-498
	AWW	Charles et al., "Prevention of Human Rhinovirus Infection by Multivalent Fab Molecules Directed against ICAM-1", Antimicrobial Agents and Chemotherapy, 2003, 1503-1508
	AXX	Behera et al., "Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection", Biochemical and biophysical research communications 280(1):188-195, Jan. 12, 2001
	AYY	Fang et al., "Antiviral Research, 53(3);pA65 March 2002, Conference/Meeting: Fifteenth International Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002
	AZZ	Harbury et al., Science, 262: 1401-1407, 1993
	AAAA	Pescini et al., Journal of Biological Chemistry, 269(2):1159-1165, 1994
	ABBB	Lou, Guang X. et al., "Humanization of an anti-ICAM-1 antibody with over 50-fold affinity and functional improvement", Journal of Immunological Methods, 275 (2003) 31-40
	ACCC	Pestov D. G. et al., "Genetic selection of growth-inhibitory sequences in mammalian cells", Proceedings of the National Academy of Science, Vol. 91, No. 26, December 20, 1994
	ADDD	Kamtekar S. et al., "Protein design by binary patterning of polar and nonpolar amino acids", Science, December 10, 1993, Vol. 262, no. 5140. pp. 1680-1685
	AEEE	Holsworth Daniel D. et al., "Antisense-designed peptides: A comparative study focusing on possible complements to angiotensin II", Peptide Research, Vol. 7, No. 4, 1994, pp. 185-193
	AFFF	Fabrice Le Gall et al., "Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding", FEBS Letters 453 (1999) 164-168

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	